key: cord-0920314-1xrfc0pj
authors: Pillay, J.; Gaudet, L.; Wingert, A.; Bialy, L.; Mackie, A. S.; Paterson, I.; Hartling, L.
title: Myocarditis and Pericarditis following COVID-19 Vaccination: Evidence Syntheses on Incidence, Risk Factors, Natural History, and Hypothesized Mechanisms
date: 2022-03-01
journal: nan
DOI: 10.1101/2022.02.28.22271643
sha: 589dc4af7c001f5a450e82f05e8017fe9c6002ab
doc_id: 920314
cord_uid: 1xrfc0pj

Objectives: Myocarditis and pericarditis are adverse events of special interest after vaccination for COVID-19. Evidence syntheses were conducted on incidence rates, risk factors for myocarditis and pericarditis after COVID-19 mRNA vaccination, clinical presentation and short- and longer-term outcomes of cases, and proposed mechanisms and their supporting evidence. Design: Systematic reviews and evidence reviews. Data sources: Medline, Embase and the Cochrane Library were searched from October 2020 to January 10, 2022; reference lists and grey literature (to January 13, 2021). Review methods: Large (>10,000) or population-based/multisite observational studies and surveillance data (incidence and risk factors) reporting on confirmed myocarditis or pericarditis after COVID-19 vaccination; case series (n[≥]5, presentation, short-term clinical course and longer-term outcomes); opinions/letters/reviews/primary studies focused on describing or supporting hypothesized mechanisms. A single reviewer completed screening and another verified 50% of exclusions, using a machine-learning program to prioritize records. A second reviewer verified all exclusions at full text, extracted data, and (for incidence and risk factors) risk of bias assessments using modified Joanna Briggs Institute tools. Team consensus determined certainty of evidence ratings for incidence and risk factors using GRADE. Results: 46 studies were included (14 on incidence, 7 on risk factors, 11 on characteristics and short-term course, 3 on longer term outcomes, and 21 on mechanisms). Incidence of myocarditis after mRNA vaccines is highest in male adolescents and young adults (12-17y: range 50-139 cases per million [low certainty] and 18-29y: range 28-147 per million [moderate certainty]). For 5-11 year-old males and females and females 18-29 years of age, incidence of myocarditis after vaccination with Pfizer may be fewer than 20 cases per million (low certainty). There was very low certainty evidence for incidence after a third dose of an mRNA vaccine. For 18-29 year-old males and females, incidence of myocarditis is probably higher after vaccination with Moderna compared to Pfizer (moderate certainty). Among 12-17, 18-29 and 18-39 year-olds, incidence of myocarditis/pericarditis after dose 2 of an mRNA vaccine may be lower when administered [≥]31 days compared to [≤]30 days after dose 1 (low certainty). Data specific to males aged 18-29 indicated that the dosing interval may need to increase to [≥]56 days to substantially drop incidence. For clinical course and short-term outcomes only one small series (n=8) was found for 5-11 year olds. In cases of adolescents and adults, the majority (>90%) of myocarditis cases involved 20-30 year-old males with symptom onset 2 to 4 days after second dose (71-100%). Most cases were hospitalized ([≥]84%) for a short duration (2-4 d). For pericarditis, data is limited but more variation has been reported in patient age, sex, onset timing and rate of hospitalization. Case series with longer-term (3 mo; n=38) follow-up suggest persistent ECG abnormalities, as well as ongoing symptoms and/or a need for medications or restriction from activities in >50% of patients. 16 hypothesized mechanisms are described, with little direct supporting or refuting evidence. Conclusions: Adolescent and young adult males are at the highest risk of myocarditis after mRNA vaccination. Pfizer over Moderna and waiting more than 30 days between doses may be preferred for this population. Incidence of myocarditis in children aged 5-11 may be very rare but certainty was low. Data on clinical risk factors was very limited. Clinical course of mRNA related myocarditis appears to be benign although longer term follow-up data is limited. Prospective studies with appropriate testing (e.g., biopsy, tissue morphology) will enhance understanding of mechanism(s). Funding and Registration no. This project was funded in part by the Canadian Institutes of Health Research (CIHR) through the COVID-19 Evidence Network to support Decision-making (COVID-END) at McMaster University. Not registered.

Case reports and surveillance signals [1] [2] [3] [4] 

pericarditis after COVID-19 vaccination appeared as early as April 2021, leading to the surveillance of adverse events of special interest following vaccination with messenger RNA (mRNA) vaccines manufactured by Pfizer and Moderna. Estimated rates of myocarditis in the United Kingdom (UK) 5 and the United States (US) 6 7 are 11 and 1-2 cases per 100,000 person-years, respectively, regardless of age.

Estimated background/expected rates of myocarditis and pericarditis following COVID-19 vaccination in the US, that is, adjusted for a 7-day risk period where most cases appear, are 0.2 and 1.4 per 1 million people, respectively. 6 Historically, myocarditis has been more prevalent in males than females, from childhood through young adulthood, 8 and this tendency was reflected in early post-COVID-19 vaccination case series. 9 10 Symptoms indicative of myocarditis or pericarditis typically include new onset and persisting chest pain, shortness of breath, and/or palpitations. 11 Diagnosis of a probable case of myocarditis usually requires elevated troponin levels and/or findings from imaging (e.g., echocardiography, magnetic resonance imaging) or other testing (e.g., ECG); histopathology for a definitive diagnosis is not usually performed. 12 Differential diagnoses, including COVID-19 infection and community-acquired myocarditis, should be considered and ruled out. 12 13 Most people experiencing these conditions will fully recover; however, in rare cases, myocarditis can lead to heart failure or asymptomatic left ventricular dysfunction.

Long-term consequences associated with pericarditis include one or more recurrences and, rarely, thickening of the pericardium and constrictive heart filling. 14 This evidence synthesis included systematic reviews of incidence rates (0 to 39 years) and risk factors for myocarditis and pericarditis after COVID-19 mRNA vaccination, evidence reviews of initial presentation and clinical course and of longer-term outcomes of cases, and a description of proposed mechanisms and their supporting evidence. Our original reviews (literature search October 6, 2021) on incidence rates, risk factors, and case presentation and short-term outcomes of myo-and/or pericarditis after COVID-19 vaccination across all vaccines, ages and sexes indicated that incident rates were little-tonone after non-mRNA vaccines and in adults 40 years and older, that rates after mRNA vaccination varied by sex, age, and dose, and that the case characteristics and clinical course of myocarditis and pericarditis differ. 15 There were no data on children aged <12 years or for people after receiving a third dose. For our review update reported herein, we refined the questions to focus on gaps and stakeholder/decision-maker priorities, specifically, mRNA vaccines, priority age and risk groups, and cases after a third vaccine dose. Where possible, we limited cases to those confirmed by medical record review and of myocarditis/myopericarditis or pericarditis rather than in combination (when data were available separately). We also expanded the scope to include evidence on longer-term outcomes. Finally, we added descriptions and studies of hypothesized mechanisms. This report focuses on the refined questions but includes findings on characteristics and short-term clinical course of myocarditis or pericarditis after any dose of the vaccine across all ages from the original review. 

We conducted these evidence syntheses following a protocol developed before screening began.

Knowledge users from the Public Health Agency of Canada (PHAC) contributed to scoping the reviews but did not participate in their conduct. We followed guidance for systematic reviews when conducting 16 and reporting 17 questions 1 and 2.

We worked with an experienced medical information specialist to develop the search strategy, which was peer-reviewed (see Acknowledgements). 18 Searches combined concepts for COVID-19, vaccines, and myocarditis/pericarditis/cardiovascular manifestations/adverse events/surveillance; each concept included various key word and Medical Subject Heading (MeSH) terms. The search was originally run on October 6, 2021 and an update was run January 10, 2022; the update search (Appendix 1) was slightly modified from the original search (e.g., adding Omicron, removing non-mRNA vaccine terms). We did not add limits for language, country, or study design, but had limits for case reports and news/newspaper articles. Using the multifile option as well as the deduping tool in Ovid, we searched . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022 McManus; see Acknowledgements) to identify potentially eligible studies on mechanisms. All studies/reports included in the original review were screened for eligibility for the revised questions in this update.

Our inclusion criteria are outlined in Table 1 . At least one dose of the vaccine needed to be w ith an mRNA vaccine; one or more other doses may have been w ith a non-mRNA vaccine. For Qs 3-5 w e included expsosure to myocarditis and/or pericarditis (combined) if there w as no data on these separately. Control/Com parator Q1: People previously vaccinated w ith mRNA COVID-19 vaccine but no longer at risk for outcome, previously vaccinated w ith other vaccines (i.e., controlling for confounders associated w ith vaccine uptake), or unvaccinated people; or no comparator. Q2: People vaccinated w ith mRNA COVID-19 vaccine but w ithout the risk/protective factor.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) diseases] and infections [e.g., recent/past SARS-CoV-2 infection], race/ethnicity) and case presentation (e.g., timing/dose/type of vaccine, diagnostics, illness severity, treatments provided, short-term outcomes). Q4: As in Q3, plus any outcomes measured ≥4 w eeks after onset of myocarditis or pericarditis (e.g., re-hospitalization, functional capacity, chest pain). Q5: Authors' summaries of any hypotheses or findings after investigating potential mechanisms (e.g., histology, experiments w ith viral spike glycoprotein of SARS-CoV-2 [encoded by mRNA vaccine]), gene panels, serology for innate and acquired immune system components, autoimmune antibodies).

Any setting and country.* Study design Q1: Large (>10,000 vaccinated people) sample or multisite/health system-based observational studies; reports or databases of confirmed case using surveillance data. Q2: Observational studies (including case control studies) w ith n ≥10 w ith the risk/protective factor; data for subset of people w ith myocarditis or pericarditis may come from passive reporting systems. Q3: Case series n≥5; data may come from medical record review of cases reported to active or passive surveillance systems (if reporting more than age, sex, and dose and type of vaccine); for Q3b w e relied first on case series reported in systematic review s and added data on cases from more recent case series or studies included for incident rates if they reported sufficient data on clinical course. Q4: Case series n≥5; data may come from medical record review of cases reported to active or passive surveillance systems. Q5: Any primary study, systematic review , or expert opinion article/letter on the topic.

Letters and commentaries w ill be included if they provide sufficient data.

English full texts.

We w ill cite those excluded based on language.

Oct 2020-onw ards (vaccines w ere authorized mid-Sept 2020).

Pre-prints w ill be included. * For questions 1 and 2, when reports collected data from similar/overlapping populations (e.g., US national surveillance data), we first included the study with the most recent data and then included additional studies if they differed in their methods (e.g., differing risk intervals [period after the vaccine where cases are counted]), differing age and/or sex stratification, use of unvaccinated or similar controls).

All reviewers undertaking screening conducted a pilot round in Excel using 300 records. We then conducted screening in DistillerSR (Evidence Partners) using structured forms. For title and abstract review, we applied the machine learning program Daisy AI which continually reprioritizes records during screening. 19 A single reviewer screened all titles/abstracts and another reviewer verified exclusions for the first 50% of records. For full text selection, a single reviewer reviewed all records, and a second reviewer verified all exclusions. Studies were further verified for inclusion during data extraction.

For question 3b, we mapped the case series by country and data source to identify the most recent and comprehensive data source for each geographic region (i.e., US, Canada, UK, Europe, and Israel).

For regions with multiple reports, we prioritized data that was most recent, most comprehensive (largest numbers), and that confirmed cases. We aimed to avoid overlap in data, i.e., the same cases reported in different sources. However, we did include sources that reported on specific sub-groups (e.g., 12 to 17

year-olds) to present more details on these groups of interest. We have noted in the evidence tables where there may be overlap in cases between reports and we avoided aggregating events/counts across studies.

We extracted all data into structured Word forms and conducted a pilot exercise with two studies for each question. Thereafter, one reviewer extracted data and another verified study eligibility and all data. Discrepancies were resolved by discussion or by a review lead (JP or LH).

For question 1, extracted data related to all elements of the eligibility criteria (Table 1 ) and data used for risk of bias assessment, focusing on methods for identifying cases (i.e., passive surveillance versus active surveillance/registry data), outcome ascertainment and confirmation/adjudication (including criteria for case definitions and classification), as well as the dosing interval and risk interval for which the events were captured. We preferred estimates of incidence compared with an unexposed group (i.e., excess incidence/risk differences) over those without a control. For question 2, we extracted data as for question 1, along with associations or subgroup analyses based on pre-existing conditions, different vaccine types/products, dosing interval, and combinations of vaccines. We extracted rates in each group . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint and (if reported) the relative effects between groups (e.g., incidence rate ratio (IRR), odds ratios), adjusted for key confounders (i.e., infection status, cardiac and immunodeficiency/autoimmune conditions) when reported.

For questions 3 and 4, we based data extraction on the evidence table presented in an existing review 9 as it covered most of the items specified under our outcomes in Table 1 . We added the following items: criteria for confirmation of cases, breakdown of cases by diagnosis (myocarditis, pericarditis, myopericarditis), case source, age included, percent with pre-existing conditions, percent admitted to an intensive care unit (ICU), percent hospitalized, number of fatalities. For question 4, we also added longerterm investigations and outcomes.

For question 5, we extracted verbatim authors' summaries of any hypotheses and, where available, findings by the authors or cited works investigating potential mechanisms (e.g., histology, gene panels, serology for innate and acquired immune system components, autoimmune antibodies, tissue biopsies, autopsy findings, etc.). We checked references used to support statements made by authors in proposing or explaining hypotheses to identify whether they provided direct empirical evidence (i.e., specific to COVID-19 mRNA vaccination). We involved three content experts who reviewed proposed mechanisms for comprehensiveness and interpretation.

For questions 1 and 2, all reviewers involved in the risk of bias assessments piloted the risk of bias tool with two papers. We used the JBI (formerly Joanna Briggs Institute) checklist for cohort studies, 20 with modifications mainly to ascertain valid risk factor measurement (Appendix 2). We focused on valid and reliable case finding and confirmation, and, for question 2, accounting for key confounders.

Assessments were completed by one reviewer and verified by another. Discrepancies were resolved by discussion or by a review lead.

For questions 3 and 4, we did not assess the risk of bias of the included case series. The intent of these questions was to characterize these patients and their clinical course without providing quantitative estimates, e.g., of incidence. The main differentiating feature between existing case series is whether they . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 1, 2022. only report on cases confirmed/verified by clinicians; we either limited inclusion to confirmed cases (questions 3a and 4) or extracted this information and considered this factor when summarizing the results (question 3b).

For question 1, we did not pool results due to heterogeneity in case finding (passive vs. active surveillance), dosing and risk intervals, age groupings, and, in some cases, some degree of overlap in cases expected between studies. We tabulated all results and compared and contrasted findings between studies based on the major differentiating population, vaccine and methodologic variables. We report the range in incidence rates across studies, or, when all rates are low, concluded that the incidence is <20 cases per million which, based on our clinical investigator input, we considered very rare. Based on input from clinicians and our knowledge users from PHAC we developed primary age categories (0-4, 5-11, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] to rely on when possible. If a study contributed more than one result within these (e.g., 20-24 and 25-29, results for each mRNA vaccine) we calculated a weighted average (e.g., by proportion of years in the age range) of the incident rates. When a study reported an incidence rate (or data to calculate this) and an IRR compared with a control/background rate, but not the difference in incidence (excess incidence over background rate), we calculated the excess incidence (i.e., crude incidence -[crude incidence/IRR]).

We assessed the certainty for each of our conclusion statements using Grading of Recommendations, Assessment, Development and Evaluation (GRADE) guidance. [21] [22] [23] We did not apply a threshold for an important incidence rate, but in general considered fewer than 20 cases per million doses to be very rare. For question 2, associations ≥1.5 (odds ratio/relative risk) were considered clinically relevant (i.e., OR <1.5 shows "little-to-no association"). Observational studies for incident rates (question 1) started at low certainty (i.e., our confidence in the incident rate is limited; the true rate may be substantially different from the estimate) and studies on risk factors (question 2) started at high certainty 21 (i.e., we are very confident that the true difference in rate between risk groups lies close to the estimate). We rated down for serious concerns about risk of bias, inconsistency/lack of consistency . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint (single study), indirectness, imprecision, and/or reporting biases. We rated down for risk of bias when only studies having high risk for case ascertainment contributed to an outcome (e.g., passive surveillance where we assume there is under-ascertainment), and for indirectness for comparisons across both sexes or if the age group reported did not match one of our groups of interest (e.g., 13 -39 year olds) and the incident rates may vary substantially among ages. We rated down for imprecision in groups with fewer people than would be expected for 1 event to occur based on estimated baseline incidence rates (e.g., a subgroup with 8000 people but reporting zero events). We considered uprating due to large incidence rates (e.g., twice or more than our 20 per million threshold) when no other major limitations were evident and we had moderate confidence in our conclusion, often reported as a range of incidences. 24 In our conclusions, we have used "probably", "may" and "uncertain" to reflect, respectively, moderate, low, or very low certainty evidence based on GRADE. When we have very low certainty we make no conclusions about specific incident rates or other outcomes.

For questions 3 and 4, we present the details for each case series in an evidence table and provide a descriptive summary. For question 5, we present a summary of the mechanisms and a more descriptive 

Two patient/public partners joined the research team (see Acknowledgements). They were not involved in decisions about the questions or outcomes, which were determined by the funders. The research leads met with these partners to present and discuss the findings and their implications. The partners co-developed with the leads key messages from their perspective.

After deduplication, our database searches on October 6 2021 and January 1 2022 retrieved 3,439 and 2,191 citations and other sources identified 18 and 805 citations. After title/abstract screening, we retrieved and screened full texts of 159 and 258 citations during each search. Forty-six studies were included in this update (Figure 1) . Findings from 12 studies from the original review 15 were carried . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. 49 50 , Q5=21 9 51-70 ); we excluded five studies that only reported on combined myo-and/or pericarditis (as we located other studies with these reported separately), [71] [72] [73] [74] [75] eight studies that did not report on confirmed cases, [76] [77] [78] [79] [80] [81] [82] [83] and three studies 84-86 that did not contribute additional data to other included studies on the same cases. Tables of study characteristics, with all data on results, and risk of bias ratings for questions 1 and 2 are in Appendix 2. Appendix 3 contains descriptions of the various national surveillance systems from which reports were collated or data collected.

We included 14 studies (reported in publications, presentations, online reports, accessible data; all are considered here as "studies" for simplicity), with 8 using active surveillance data sources (e.g., medical records/ registries) and 6 using passive reporting systems. Data came from the US, Canada, the UK, Israel, Denmark, Singapore, and internationally (Moderna Global Safety Database). Four studies used the US VAERS data source for cases, and there was overlapping populations in analyses for 5-11 43 44 and 12-17 25 29 year olds where two reports were included for each because they applied different risk intervals (7-days and any duration). Four studies included a comparator group or background rate to estimate excess incidence rates. All studies on myocarditis reported on incident rates by age and sex; the only study reporting on pericarditis by age (5-11 year-olds) reported data across both sexes. 39 Risk of bias was rated as some concerns (n=2) and high (n=6, mostly from lack of adjustment for variables other than age and sex) for studies using data from active surveillance systems and high for all six studies using passive surveillance data. Table 2 includes the results by study, the conclusions for each age and sex category, and the GRADE certainty assessments. We refer to studies by their source of adverse event data and the date of data collection; references for each study using this format are in Appendix 3.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint For 5-11 year-old males and females, the incidence of myocarditis after vaccination with Pfizer may be fewer than 20 cases per million in both groups (low certainty). The incidence of myocarditis after mRNA vaccines is highest in male adolescents and young adults (12-17y: range 50-139 cases per million [low certainty] and 18-29y: range 28-147 per million [moderate certainty]). For 18-39 year-old males, the incidence of myocarditis may be between 25 and 82 cases per million (low certainty). Among females 18-29 years of age, the incidence of myocarditis after vaccination may be less than 20 cases per million (low certainty). We are very uncertain about the incidence of myocarditis after vaccination with mRNA vaccines in 12-17 year-old females, 30-39 year-old males and females, and in 18-39 year old females (very low certainty from risk of bias and inconsistency).

Among ≥40 year old males, the incidence of myocarditis after a third dose of an mRNA vaccines may be fewer than 20 cases per million (low certainty). For 13-39 year-old males or females and ≥40 year-old females, we are uncertain about the incidence of myocarditis after a third dose of an mRNA vaccine due to concerns about imprecision and inconsistency from multiple studies (very low certainty).

Based on a single study only reporting across both sexes, we are uncertain about the incidence of pericarditis after Pfizer vaccination in 5-11 year old males and females (very low certainty).

In this question, we assessed the relative differences in outcomes across subgroups. It is important to note, however, that these relative results must be taken in context with question 1 findings reporting on incidence; the relative differences in subgroups in females and older age groups should be given less weight in policy decision-making, based on the very low-to-no incidence of myocarditis after mRNA vaccination in these groups. Table 3 includes the results by study (n=7), the conclusions for risk factor by age and (when available) sex, and the GRADE certainty assessments. We refer to studies by their source of adverse event data and the date of data collection; references for each study using this format are in Appendix 3.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint

For 18-29 year-old males and females, and 18-39 year-old males, the incidence of myocarditis is probably higher after vaccination with Moderna compared to Pfizer (moderate certainty). For 18-39 year-old females, the incidence of myocarditis may be higher after vaccination with Moderna compared to Pfizer (low certainty). For 30-39 year-old males and females, there may be little-to-no difference in the incidence of myocarditis after vaccination with Moderna compared to Pfizer (low certainty). Among ≥40 year-old males and females, there is probably little-to-no difference in risk of myocarditis after vaccination with Moderna compared to Pfizer (moderate certainty).

Among 18-29 and 18-39 year-old adults, and 18-29 year-old males, there may be little-to-no difference in the incidence of myocarditis/pericarditis after mRNA vaccination with a heterologous dose 2 (mixed Moderna and Pfizer with either for dose 2) compared to homologous dose 2 (low certainty). For adults ≥40 years old, we are uncertain about any difference in the incidence of myocarditis/pericarditis after mRNA vaccination with a heterologous dose 2 compared to homologous dose 2 (very low certainty).

Among 12-17, 18-29 and 18-39 year-old individuals, the incidence of myocarditis/pericarditis after dose 2 of an mRNA vaccine may be lower when administered ≥31 days compared to ≤30 days after dose 1 (low certainty). Data specific to males aged 18-29 indicated that the dosing interval may need to increase to ≥56 days to substantially drop incidence. For 18-29 year-olds, the proportional decrease in incidence of myocarditis/pericarditis after dose 2 of an mRNA vaccine when administered ≥31 days compared to ≤30 days after dose 1 may be similar for Moderna and Pfizer. This proportional decrease may be smaller with Moderna compared to Pfizer for 18-39 year olds (low certainty). Among ≥40 year-old people, incidence of myocarditis/pericarditis after dose 2 of an mRNA vaccine may be higher when administered ≥31 days compared to ≤30 days after dose 1 (low certainty). In this group, the proportional increase in incidence of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

We are uncertain if people with immunocompromise or inflammatory conditions have a different risk of myocarditis after mRNA vaccination (very low certainty from single studies using passive reporting systems without case confirmation and having inadequate sample sizes).

For this update question, we included one study (also included for question 1) reporting data on 5-11 year-olds with confirmed myocarditis. 43 No study was found that reported on case presentation after a third dose or for those with a previous experience of myocarditis after a COVID-19 vaccine. In a series of 5-11 year olds receiving Pfizer (n=8), 50% were male and median age was 9 (range 6-11) years.

Race/ethnicity was not reported. Six children presented after their second dose and median time to present was 3 days. Seven presented with chest pain; of six tested three had abnormal ECG findings; and of five tested one had an abnormal echocardiogram. Of six with known outcomes, five had complete resolution of symptoms. Data is presented in the last column of Table 4 .

From the original review, we report on 10 case series (6 published as case series 31-36 and 4 included in Q1 but having relevant data on cases 25-28 ) reporting on a total of 10,264 cases (median 22, range 6-5611) of myocarditis or pericarditis. All reports except the one using EudraVigilance data from the European Economic Area included clinician-confirmed cases. Table 4 (myocarditis or myopericarditis) and Table 5 (pericarditis) include data from the 10 case series. Table 4 also contains data from the case series of 5-11 year-olds included for the update question 3a.

Most case series focused on myocarditis (10 reports, n=5,955). Across the case series, the majority of cases (often >90%) involved males with reported median age most often between 20 and 29 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint years; confirmed cases ranged from 12 to 56 years. Race/ethnicity was not reported in any case series.

Time between last vaccine and symptom onset was on average 2 to 4 days, and the majority (71-100% across reports) presented after a second dose. Most cases presented with chest pain or pressure, and troponin elevation; when tested a minority (14-29% across studies) showed left ventricular dysfunction (i.e., LVEF<50%). Three reports provided data for pericarditis (n=4,309; > 98% unconfirmed). The majority involved males; however, there was variation across reports (54 to 91%). Median age (59 years) was only reported in one small series (n=37). The same series reported a median interval of 20 days between last vaccine and symptom onset, with 60% presenting after the second vaccination. Hospitalization varied (35% and 73% reported in two series with a total of 59 cases); one series (n=37) reported 3% admitted to ICU and 1 day for median length of stay. One series (n=37) reported 0 fatalities, and a larger series of unconfirmed cases (n=4,250) reported 15 deaths (0.4%).

Three reports 39 49 50 reported on 38 cases with follow-up approximately 90 days after diagnosis of myocarditis following vaccination with an mRNA COVID-19 vaccine ( Table 6 ). Among 14 patients hospitalized for myocarditis after vaccination in the two smaller case series (n=14), patients were males aged 13-19 years and followed up for ~90-105 days after diagnosis. In the case series of five patients, 49 repeat cardiac MRI was undertaken in two patients, with both showing persistent but decreased late gadolinium enhancement similar to the distribution of the initial MRI but no new abnormalities. Further, three patients had self-resolving mild . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint intermittent chest pain after discharge, one had recurrent chest pain after discontinuing the NSAID prescribed at discharge, and three had recurrent symptoms that prompted emergency department visits post-discharge. In the series of nine patients, 50 none were on heart failure medication at 90 day follow-up. In the larger case series (n=43), 39 among cases of myocarditis and/or pericarditis (n=2) with long-term follow-up (n=24, mean follow-up time 89 days), the majority were males aged 12 to 17 years. Nine out of 18 patients receiving ECG had abnormal findings; 2 out of 17 with an echocardiogram showed abnormalities. Few (8%) patients were on medications such as NSAIDs and colchicine after discharge, and 46% had no symptoms, medications, or exercise restrictions at follow-up.

We included 21 papers, 9 51-70 including narrative reviews, opinion pieces, letters to the editor, case reports, case series, a retrospective study, and a protocol for a prospective observational study. Across the included papers, we identified 16 hypotheses that are presented in Table 7 . Additional details for each hypothesis are available in Appendix 4. All hypotheses related to myocarditis rather than pericarditis. The most commonly discussed hypotheses were: hyper immune/inflammatory response; autoimmunity triggered by molecular mimicry or other mechanism; delayed hypersensitivity (serum sickness); eosinophilic myocarditis; and hypersensitivity to vaccine vehicle components (e.g., polyethylene glycol [PEG] and tromethamine; lipid nanoparticle sheath). A number of novel hypotheses were put forward by single papers, such as low residual levels of double-strand RNA (dsRNA), hyperviscosity inducing cardiac problems, and strenuous exercise induced secretion of proinflammatory IL-6. A number of papers discussed observed differences in incidence by sex which could be attributed to sex steroid hormones or under-diagnosis in females.

Adolescent and young adult males are at the highest risk of myocarditis after mRNA vaccination and the incidence may be as high as 140 cases per million (1.4 per 10,000). For 5-11 year-old males and females, the incidence of myocarditis after vaccination with Pfizer may be fewer than 20 cases per million although the evidence is of low certainty. Data on incidence rates after a third vaccine dose is limited. For 18-29 year-old . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint males and females, incidence of myocarditis is probably higher after vaccination with Moderna compared to Pfizer (moderate certainty). Among 12-17, 18-29 and 18-39 year-olds, incidence of myocarditis/pericarditis after dose 2 of an mRNA vaccine may be lower when administered ≥31 days compared to ≤30 days after dose 1 (low certainty). Data specific to males aged 18-29 indicated that the dosing interval may have needed to increase to ≥56 days to substantially drop incidence. Data on other potential risk factors was very limited. The clinical course of myocarditis in children 5-11 years, for those after a third dose, and for those with previous myocarditis after mRNA vaccination is largely unknown. Though the short-term course has consistently demonstrated to be quite mild and self-limiting, more data on longer-term prognosis is needed.

Several mechanisms have been hypothesized to account for COVID-19 mRNA vaccineassociated myocarditis. The hyper immune/inflammatory response hypothesis raises the question of whether the response is a systemic process or local to the heart. Multi-organ injury is commonly seen in systemic inflammation, however, a cardiac insult is easier to detect due to chest pain symptoms and measurable changes in cardiac biomarkers and imaging. While autoimmunity triggered by molecular mimicry or other mechanism is among the more commonly discussed hypothesis, the observed response timing after the second vaccine dose (1-5 days) is considered early for this type of mechanism. If mRNA vaccine related myocarditis occurs from exposure to partial antigens (epitopes of SARs-CoV2 spike protein), then this mechanism should also account for myocarditis after COVID infection. Additionally, vaccines using adenoviral vector-based platforms produce the spike protein but have not been implicated in causing higher than background rates of myocarditis. The delayed hypersensitivity hypothesis is supported by earlier work of other viruses (e.g., coxsackieviruses, echoviruses). Eosinophilic myocarditis is unlikely a major cause of post-vaccination cardiac inflammation as the rate of myocarditis would be expected to approximate the rate of true allergic reactions to the vaccine. Hypersensitivity to vaccine vehicle components is a commonly discussed hypothesis; however, this is not likely to account for a major mechanism as allergic reactions have been very rare with the vaccines. The different incidence seen across sexes also suggests a non-allergic reaction predominating. The mechanism(s) may be very similar to that for myocarditis with COVID-19 infection, but at a lower incidence due to the smaller quantity of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint spike protein exposure. Therefore, exploring some of the mechanisms in the COVID-19 myocarditis literature may be valuable. One potential hypothesis that was not described in the examined articles relates to microvessel partial or complete thrombosis with multi-focal ischemic injury related to endothelial ACE2 expression and fibrin-platelet interactions in susceptible individuals.

Several limitations exist in the mechanistic literature we identified: i) little direct empiric evidence was available to support or refute the proposed hypotheses; where direct empiric evidence was available, it often derived from case reports or small series, ii) when assessing laboratory findings in case reports/series/retrospective studies, it is not clear whether any differences seen (e.g., increases in NK cells, autoantibodies) reflect a causal pathological immune response or reactive adaptive responses to the myocardial inflammation, iii) the emergence of new studies refuting some of the proposed mechanisms;

for example, articles stating no reports of eosinophilia, are out-dated due to reports finding evidence of this, iv) there has been a lack of invasive investigations (e.g., biopsy, tissue morphology, special studies to detect injury, immune activity, virus, etc.) given the typically mild course of the clinical conditions observed, and v) it is difficult to confirm a causal link; for example, an important proportion of cases observed or reported may not be vaccine-related and this will contribute to the heterogeneity of presentations, clinical characteristics, and resulting hypotheses. Choi et al. 87 described a fatal case of myocarditis after mRNA vaccination and compared the case to another fatality reported by Verma et al. 69 both of which had comprehensive clinicopathological analysis. The two cases were remarkably different, suggesting "that myocarditis after COVID-19 mRNA vaccination is heterogeneous, both clinically and histologically." 87 Moreover, this data also supports the concept that post-COVID-19 vaccination related myocarditis can arise from different mechanisms.

Several key messages were co-developed with our patient partners to reflect their perspectives.

First, the highest risk for myocarditis after COVID-19 vaccination exists for male adolescents and young adults (12-29y) although it is likely still small and occurrences appear to be quite mild with full recovery. There is probably some benefit for this population to receive Pfizer rather than Moderna and there may be value for dosing to be prolonged to some degree. Second, clear and effective communication . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint of the risks (rates of myocarditis and likely clinical course) and benefits from vaccination, and the availability of good alternatives (e.g., non-mRNA vaccines) will be critical for young males and their parents. Finally, more research on children and what personal risk factors (e.g., pre-existing conditions) may put someone at higher risk is urgently needed.

There are several strengths of this review. A comprehensive, peer-reviewed search strategy was used and inclusion of grey literature captured very recent data. A second reviewer screened the most relevant (based on machine learning) citations, and verified all data and risk of bias assessments. GRADE assessments were based on team consensus including clinical experts. Patient partners reviewed the evidence and developed interpretations from the patient perspective. The main limitation is that in the era of COVID-19 the literature base is evolving with incredible rapidity and new evidence will emerge; nevertheless, there was some moderate certainty evidence found in this review. We are unaware of any other comprehensive examination, and critique, of existing descriptions of the potential mechanisms that may be involved in COVID-19 vaccine-associated myocarditis. We may have missed some mechanistic studies because of the addition of this question for this update, after the original review was completed.

Adolescent and young adult males are at the highest risk of myocarditis after an mRNA vaccination. Pfizer over Moderna and waiting more than 30 days between doses may be preferred for this population. As the incidence of myocarditis after mRNA vaccination remains a rare adverse event, the findings must be considered alongside the overall benefits of vaccination and with detailed risk-benefit analyses to support policy recommendations for optimal dosing intervals and vaccine products for different populations. As the COVID-19 pandemic enters its third year, continued surveillance of myocarditis after mRNA vaccines, especially in younger ages, after dose 3 (and subsequent doses) and in previous cases is needed to support continued decision making for COVID-19 boosters. Additional monitoring of populations with clinical comorbidities of interest (e.g., cardiac conditions, previous history . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint of myocarditis, immunocompromised, etc.) is also needed in order to protect the already medically vulnerable. Long term follow-up of myocarditis cases is needed to better understand the natural history including disease recurrence. Finally, multi-center prospective studies with appropriate testing (e.g., biopsy, tissue morphology) will enhance understanding of the mechanism(s) of myocarditis postvaccination which in turn will help identify and guide recommendations for those who may be at higher risk.

Contributors: JP, LH, AM and IP designed the study. JP, LH, LB, LG, and AW screened citations for inclusion and were involved in data extraction and interpretation. JP, LB, LG and AW were involved is risk of bias assessments. All authors were involved in interpretation of the data. JP wrote the draft manuscript with input from all authors. All authors approved the final version of the manuscript. LH and JP are the guarantors of this manuscript and accept full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. 

Evidence Network to support Decision-making (COVID-END) at McMaster University and the SPOR Evidence Alliance. The funders provided input on the design of the study, but did not take part in the collection, analysis, or interpretation of data. They reviewed a report generated from the findings but did not make decisions about submission of the article for publication.

This review was developed through the analysis, interpretation and synthesis of scientific research and/or systematic reviews published in peer-reviewed journals, institutional websites and other distribution channels. This document may not fully reflect all the scientific evidence available at the time this report was prepared. Other relevant scientific findings may have been reported since completion of this synthesis report.

SPOR Evidence Alliance, COVID-END and the project team at ARCHE make no warranty, express or implied, nor assume any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, data, product, or process disclosed in this report. Conclusions drawn from, or actions undertaken on the basis of, information included in this report are the sole responsibility of the user.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare support from the funders for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval: This research did not involve human research participants and thus did not require ethics approval.

The lead authors of this work, JP and LH, affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned in the protocol have been explained. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 1, 2022. ; https://doi.org/10.1101/2022.02.28.22271643 doi: medRxiv preprint 

In the plain-language conclusions, we have used " probably", " may be" and " uncertain" to reflect level of certainty in the evidence based on GRADE of moderate, low, or very low, respectively. a Rated down for potential risk of bias because all data from passive reporting systems. Incidence rates may be underestimated. b Rated up for estimated incidence likely to be more than twice our clinically important threshold of 20 cases per million, highly unlikely to be seen by chance and credible to be higher than for other age categories. (Citation 24 ) c Rated down for inconsistency for only one study or for a large incidence range within one age/sex category d Rated down for all contributing studies as being at high risk of bias e Rated down for indirectness of findings to entire population, based on large differences in estimates in analyses for males across age groups indicating one estimate (or even a range of estimates) for all ages (for both sexes or males) is not credible. f All contributing studies rated at high risk of bias, however potential biases unlikely to change conclusion so did not rate down. We are uncertain if individuals with immunocompromise have increased risk of myocarditis after mRNA vaccination.

b,c,d 1 T his study reported IRRs calculated using a self-controlled case series design. In this study design, individuals serve as their own controls and risk estimates in pre-and post-intervention intervals are calculated within individuals, rather than across individuals. 2 Because of the large overlap in data between males 18-29y and 18-39y, we only downrated 18-29y once for inconsistency despite the large differences in effects reported between studies. 3 Weighted averages across age groups were calculated based on contribution of each age to the review-level age category.

In the plain-language conclusions, we have used " probably", " may be" and " uncertain" to reflect level of certainty in the evidence based on GRADE of moderate, low, or very low, respectively. a Rated down for indirectness to whole population, based on large differences in estimates in analyses for males across age groups indicating one estimate (or even a range of estimates) for all ages (for both sexes or males) is not credible. b Rated down for risk of bias from use of passive surveillance and lack of case verification c Rated down for inconsistency due to only one study providing estimates d Rated down for imprecision for small sample size (<10,000 per group) or very low event rate. Alcohol or drug dependence = 5 (14%); coronary artery disease = 4 (11%); cancer = 5 (14%); heart failure = 2 (5%); cirrhosis = 1 (3%); chronic kidney disease = 4 (11%); COPD = 4 (11%); diabetes = 4 (11%); hypertension = 18 (49%); autoimmune disease = 3 (8%) 

Abbre viations: C MR = cardiovascular magnetic resonance imaging; ICU = intensive care unit; LVEF = left ventricular ejection fraction; NR = not reported; NSAID = non-steroidal antiinflammatory drugs.

Surveillance of Myocarditis (Inflammation of the Heart Muscle) Cases Between

Symptomatic Acute Myocarditis in 7 Adolescents After Pfizer-BioNTech COVID-19 Vaccination

Israel examining heart inflammation cases in people who received Pfizer COVID shot

Background Rates of Adverse Events of Special Interest for Monitoring COVID-19 Vaccine

Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring

Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines

The effects of gender and age on occurrence of clinically suspected myocarditis in adulthood

Myocarditis With COVID-19 mRNA Vaccines

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices -United States

Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review

Good prognosis for pericarditis with and without myocardial involvement: results from a multicenter, prospective cohort study

Myocarditis and Pericarditis following COVID-19 Vaccination: Rapid Systematic Review of Incidence, Risk Factors, and Clinical Course

AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement

An evaluation of DistillerSR's machine learning-based prioritization tool for title/abstract screening -impact on reviewerrelevant outcomes

Checklist for Cohort Studies

GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

The GRADE Working Group clarifies the construct of certainty of evidence

Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records

Risk of myocarditis following sequential COVID-19 vaccinations by age and sex

Myocarditis after mRNA-1273 vaccination: A populationbased analysis of 151 million vaccine recipients worldwide

Adverse events among children ages 5-11 years after COVID-19 vaccination: updates from vsafe and the Vaccine Adverse Event Reporting System (VAERS)

COVID-19 vaccine safety updates: Primary series in children and adolescents ages 5-11 and 12-15 years, and booster doses in adolescents ages 16-24 years

Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel

Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination

Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Adverse events among children ages 5-11 years after COVID-19 vaccination: updates from vsafe and the Vaccine Adverse Event Reporting System (VAERS)

Cardiac MRI Findings of Myocarditis After COVID-19 mRNA Vaccination in Adolescents

Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children

68 Ga-DOTATOC digital-PET imaging of inflammatory cell infiltrates in myocarditis following COVID-19 vaccination

Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level

Myocarditis After SARS-CoV-2 Vaccination: A Vaccine-Induced Reaction?

Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age

Biopsy-proven lymphocytic myocarditis following first mRNA COVID-19 vaccination in a 40-year-old male: case report

Crosstalk among strenuous exercise, IL-6 and S-Protein Based Vaccines for COVID-19 may explain the rare adverse effects of myocarditis and thrombosis in recently vaccinated young people. A prospective observational study

Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis

Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms

Post RNA-based COVID vaccines myocarditis: Proposed mechanisms

The pathogenesis of potential myocarditis induced by COVID-19 vaccine

Hypersensitivity myocarditis and COVID-19 vaccines

Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA

Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?

Evaluating the relationship between myocarditis and mRNA vaccination

Eosinophilic Myocarditis Following Coronavirus Disease 2019 (COVID-19) Vaccination

Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults

Potential implications of lipid nanoparticles in the pathogenesis of myocarditis associated with the use of mRNA vaccines against SARS-CoV-2

Myocarditis after Covid-19 mRNA Vaccination

Response to case report on myocarditis and pericarditis after COVID-19 vaccination

Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination

Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects

Myopericarditis in young adults presenting to the emergency department after receiving a second COVID-19 mRNA vaccine

Myocarditis and/or Pericarditis Risk After mRNA COVID-19 Vaccination: A Canadian Head to Head Comparison of BNT162b2 and mRNA-1273 Vaccines

Risk of Myopericarditis following COVID-19 mRNA vaccination in a Large Integrated Health System: A Comparison of Completeness and Timeliness of Two Methods

Myocarditis and Pericarditis in Adolescents after First and Second doses of mRNA COVID-19 Vaccines

Safety Monitoring of mRNA Vaccines Administered During the Initial 6 Months of the U.S. COVID-19 Vaccination Program: Reports to Vaccine Adverse Events Reporting System (VAERS) and v-safe

Safety and Effectiveness of BNT162b2 mRNA Covid-19 Vaccine in Adolescents

Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature

Cardiac Inflammation after COVID-19 mRNA Vaccines: A Global Pharmacovigilance Analysis

Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types

Comparison of adverse events between COVID-19 and Flu vaccines

The safety profile of COVID-19 vaccinations in the United States

COVID-19 Vaccine Safety in Children Aged 5-11 Years -United States

Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings

One patient with 12 day onset had history of headache and gastrointestinal sy mptoms 3 or 4 day s before chest pain; potential v iral sy ndrome Patients with chest pain on presentationPatients with other sy mptoms (e.g., myalgia, f atigue, fever) Repeat cardiac MRI, n 2 (40%) NR 1 (4%) Characteristics of repeat cardiac MRI 2 performed, both stable biventricular size and function; persistent, but decreased, LGE that was similar in distribution to the initial MRI; and an absence of new areas of abnormality

Normal findings Symptoms such as chest pain, n 3 (60%); mild intermittent self-resolving chest pain after discharge; in one patient recurrent symptoms occurred after discontinuation of the NSAID prescribed at discharge